Lung Cancer |

The Analysis of Volatile Organic Compound Profiles in the Breath as a Biomarker of Lung Cancer FREE TO VIEW

Peter Mazzone, MD; Xiaofeng Wang, PhD; Paul Rhodes, PhD; Ray Martino, PhD; Sung Lim, PhD; Mary Beukeman; Meredith Seeley; Humberto Choi, MD; James Jett, MD
Author and Funding Information

Cleveland Clinic, Cleveland, OH

Chest. 2013;144(4_MeetingAbstracts):645A. doi:10.1378/chest.1703380
Text Size: A A A
Published online


SESSION TITLE: Biomarkers in Lung Cancer

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, October 27, 2013 at 10:45 AM - 11:45 AM

PURPOSE: Determine the accuracy of colorimetric sensor array derived volatile organic compound profiles of the exhaled breath for the identification of patients with lung cancer.

METHODS: 4L of the end-tidal portion of the exhaled breath of subjects performing tidal breathing was exposed to a colorimetric sensor array with images of the array taken at 6 defined intervals. Lung cancer subjects were biopsy confirmed and had not received treatment. Control subjects had indeterminate lung nodules, proven to be benign, or had risk factors for the development of lung cancer. Subjects were recruited from clinics at the Cleveland Clinic and National Jewish Hospitals. Logistic regression and logistic additive regression models were built. Models were validated using repeated random partition or bootstrap out-of-bag estimation.

RESULTS: 51 subjects with lung cancer and 99 control subjects were included in the analysis. 27 of the lung cancers were adenocarcinoma and 17 were squamous cell carcinoma. The C-statistic for models assessing cancer vs. control, adenocarcinoma vs. control, and squamous cell carcinoma vs. control using the sensor responses to breath only were 0.851, 0.903, and 0.947. When COPD was included in the models the values rose to 0.888, 0.932, and 0.974 respectively. The validated C-statistics were 0.763, 0.820, and 0.870 respectively.

CONCLUSIONS: Colorimetric sensor array derived volatile organic compound profiles of the exhaled breath can accurately distinguish the breath of people with lung cancer from those of relevant controls.

CLINICAL IMPLICATIONS: An accurate exhaled breath biomarker of lung cancer could be developed into a clinically useful test.

DISCLOSURE: Peter Mazzone: Grant monies (from industry related sources): This study is industry sponsored. Paul Rhodes: Employee: CEO of industry sponsor of study Ray Martino: Employee: COO of industry sponsor of the study Sung Lim: Employee: Scientist from industry sponsor of study The following authors have nothing to disclose: Xiaofeng Wang, Mary Beukeman, Meredith Seeley, Humberto Choi, James Jett

The study is evaluating a breath test for accuracy in identifying lung cancer. The breath test is considered research only.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543